EU, AstraZeneca and lung cancer
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed a feedback from the European Medicines Agency, the pharma company said Tuesday.
European markets are set to open higher on Tuesday, in a shortened trading session for Christmas Eve. London's FTSE 100 is ...
Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy ...
The Wall Street Journal on MSN9d
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing PermissionIn one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
13d
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung ...
Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback